ORANGE, Calif., July 30, 2025 /PRNewswire/ — Gnosis, a Southern California-based diagnostic lab advancing women’s health through molecular innovation, today announced the national launch of EdenDx, which stands for Early Detection for Endometrial Neoplasia, the first commercially available non-invasive liquid-based cytology test in the United States for early-stage endometrial cancer detection.

In a study conducted in Uganda and published in JAMA Surgery, researchers from Karolinska Institutet evaluated a new surgical method for treating groin hernias in women. The method could become an alternative in resource-limited settings where laparoscopic techniques are not generally available.

ASPIVIX has announced a new partnership with AGHealth to launch Carevix, its MHRA-approved non-traumatic suction cervical stabiliser, in the United Kingdom. The company says this milestone marks a significant advance in UK women’s healthcare, offering a modern and clinically validated alternative to the traditional cervical tenaculum.

Camgenium, a leading medical device software company, has announced that its software product, ‘Reassure Pregnancy’, can improve outcomes for pregnant women at risk of pre-eclampsia through at-home monitoring.

First-Ever Non-Surgical Permanent Birth Control System Gains CE Mark, Paving the Way for a New Era in Reproductive Health

Lilli Health, a company that coined the term Low Insulin Lifestyle [LILLI] created to help educate, treat and manage individuals with polycystic ovary syndrome (PCOS), has announced the launch of the Lilli App backed by decades of scientific research as the first-ever comprehensive platform focused on lowering insulin levels to reverse PCOS symptoms.

A new point of care test for pre-eclampsia is set to revolutionise testing for suspected pre-eclampsia in maternity units across the UK, aiding early detection and prognosis in pregnant women between 20-37 weeks of gestation.